BridGene Biosciences Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor BGC515

San Jose, CA, Mar. 7, 2024 – BridGene Biosciences, Inc., a pioneer in the development of covalent small molecule drugs for traditional “hard-to-drug” targets, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for the clinical study of its TEAD inhibitor BGC515 for the treatment of cancers harboring genetic mutations in the hippo signaling pathway.     "We are pleased to announce the FDA acceptance of our IND application for BGC515 and look forward to initiating this Phase I clinical study to evaluate the safety and efficacy profile of BGC515 in patients with advanced solid tumors," stated Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences. "Discovered through our unique chemoproteomic platform, IMTAC™, the TEAD inhibitor BGC515 represents a significant breakthrough. The FDA's endorsement of this IND not only validates our innovative platform but also highlights a critical step forward in our mission to develop pioneering treatments for cancer patients."     About BridGene Biosciences BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By using its proprietary chemoproteomic platform, IMTAC™, BridGene is able to screen small molecules against all proteins in live cells to discover drug candidates for high value and previously undruggable targets. For this purpose, BridGene takes advantage of its proprietary, diverse covalent library of tagged, drug-like small molecules. The ultimate goal is to enable breakthrough small-molecule drug discovery and to expand the mechanisms to treat diseases, with targets previously inaccessible to small molecules. BridGene is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit https://bridgenebio.com/.     Contact Tiberend Strategic Advisors, Inc. Daniel Kontoh-Boateng (investors) 862-213-1398 [email protected]   Dave Schemelia (media) [email protected] 609-468-9325

The release as fetched from its publisher. bridgenebio.com ↗